ATE101033T1 - Wirkstoff-harzkomplexe mit verzoegerter freigabe. - Google Patents

Wirkstoff-harzkomplexe mit verzoegerter freigabe.

Info

Publication number
ATE101033T1
ATE101033T1 AT89870168T AT89870168T ATE101033T1 AT E101033 T1 ATE101033 T1 AT E101033T1 AT 89870168 T AT89870168 T AT 89870168T AT 89870168 T AT89870168 T AT 89870168T AT E101033 T1 ATE101033 T1 AT E101033T1
Authority
AT
Austria
Prior art keywords
drug
delayed
release active
resin complexes
resin
Prior art date
Application number
AT89870168T
Other languages
English (en)
Inventor
William Joseph Kelleher
Anthony Earl Carpanzano
Original Assignee
Richardson Vicks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Vicks Inc filed Critical Richardson Vicks Inc
Application granted granted Critical
Publication of ATE101033T1 publication Critical patent/ATE101033T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT89870168T 1988-11-02 1989-10-31 Wirkstoff-harzkomplexe mit verzoegerter freigabe. ATE101033T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/265,910 US4996047A (en) 1988-11-02 1988-11-02 Sustained release drug-resin complexes
EP89870168A EP0367746B1 (de) 1988-11-02 1989-10-31 Wirkstoff-Harzkomplexe mit verzögerter Freigabe

Publications (1)

Publication Number Publication Date
ATE101033T1 true ATE101033T1 (de) 1994-02-15

Family

ID=23012384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89870168T ATE101033T1 (de) 1988-11-02 1989-10-31 Wirkstoff-harzkomplexe mit verzoegerter freigabe.

Country Status (11)

Country Link
US (1) US4996047A (de)
EP (1) EP0367746B1 (de)
JP (1) JP2941314B2 (de)
AT (1) ATE101033T1 (de)
AU (1) AU638420B2 (de)
CA (1) CA2001859C (de)
DE (1) DE68912882T2 (de)
DK (1) DK175659B1 (de)
IE (1) IE62765B1 (de)
NZ (1) NZ231229A (de)
PH (1) PH26699A (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
HUT74642A (en) * 1990-12-21 1997-01-28 Richardson Vicks Inc Polyamine drug-resin complex
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
IT1250736B (it) * 1991-08-01 1995-04-21 Zambon Spa Processo per la preparazione dell'acido 5-(2',4'-difluorofenil) salicilico in forma ii pura
SE9103110D0 (sv) 1991-10-24 1991-10-24 Kabi Pharmacia Ab New drug formulation
US5492700A (en) * 1991-11-26 1996-02-20 Warner-Lambert Company Process and composition for the development of controlled release gemfibrozil dosage form
IT1252185B (it) * 1991-12-11 1995-06-05 Therapicon Srl Preparazioni farmaceutiche a liberazione programmata
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
CA2063499C (en) * 1992-03-19 1996-06-18 Leon Edward St. Pierre Ingestible polymeric phosphonium salts for the lowering of blood cholesterol
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
TW237386B (de) * 1992-04-15 1995-01-01 Ciba Geigy
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
EP1016673B1 (de) * 1992-10-02 2006-02-01 Genetics Institute, LLC Zusammensetzung, welche den Koagulationsfaktor VIII beinhalted; Verfahren zu deren Herstellung und die Benutzung eines Oberflächenaktiven Stoffes als Stabilisator
KR0157280B1 (ko) * 1992-11-06 1998-11-16 나까토미 히로타카 하부소화관 방출성의 경구의약제제
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2122286A1 (en) * 1993-04-28 1994-10-29 Hiroshi Matoba Solid preparation and its production
ZA944949B (en) * 1993-07-12 1995-04-05 Smithkline Beecham Corp Matrix-entrapped beadlet preparation
EP0664699A1 (de) * 1993-08-13 1995-08-02 Vitaphore Corporation Arzneimittelabgabesystem auf der Basis von Hydrogelmikrokugeln
EP0727984B1 (de) * 1993-11-18 2003-06-25 Sirtex Medical Limited Zubereitung mit gesteuerter freisetzung
DE4402379C2 (de) * 1994-01-27 1997-09-25 Lohmann Therapie Syst Lts Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung
US6322815B1 (en) 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
US6491945B1 (en) * 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
CA2269679A1 (en) * 1996-12-20 1998-07-02 Warner-Lambert Company Antitussive drugs delivered by partially coated ion exchange resins
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
EP1140037A1 (de) * 1999-01-07 2001-10-10 ELAN CORPORATION, Plc Multipartikuläre orale dosisformen
EP1200129B1 (de) * 1999-07-14 2008-10-15 Schering-Plough Ltd. Maskieren des geschmacks der oralen flüssigen chinolon-zubereitungen mit ionenaustauscherharzen
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN102716101A (zh) 1999-10-29 2012-10-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
AU2002258563A1 (en) * 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
WO2003039488A2 (en) * 2001-11-09 2003-05-15 Lauren Charous A method for treating inflammatory bowel disease
WO2003086353A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
EP1599187A4 (de) * 2002-11-26 2007-08-08 Univ Maryland Wässriges arzneistoffabgabesystem mit anhaltenderwirkstofffreigabe für stark wasserlösliche elektrolytika
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
WO2005013934A2 (en) * 2003-07-28 2005-02-17 Novartis Consumer Health S.A. Taste-masked composition of cationic exchange resin
CA2537607A1 (en) 2003-09-03 2005-03-17 Mallinckrodt Inc. Granular sustained release preparation and production thereof
EP2184058B1 (de) 2003-09-26 2012-02-08 ALZA Corporation Arzneistoffcoating mit hohem Wirkstoffanteil sowie Methoden zu dessen Herstellung
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20070232695A1 (en) * 2004-01-28 2007-10-04 Collegium Pharmaceutical, Inc. Gelled Periodontal Anesthetic Preparation
US20050226920A1 (en) * 2004-04-13 2005-10-13 Kirk Voelker Method of decreasing nicotine withdrawal symptoms during smoking cessation.
KR20070058381A (ko) * 2004-04-27 2007-06-08 메디시노바, 인크. 염증성 질환 치료용 페녹시알킬카르복실 산 유도체
CA2576232C (en) * 2004-05-14 2009-10-27 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
WO2005115336A2 (en) * 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
WO2006101536A1 (en) * 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
EP1893175A1 (de) * 2005-06-09 2008-03-05 Upm Pharmaceuticals, Inc. Wässriges arzneistoffabgabesystem mit anhaltender wirkstofffreigabe für stark wasserlösliche elektrolytika
JP2008546835A (ja) * 2005-06-28 2008-12-25 ユ セ ベ ソシエテ アノニム 複数の活性薬物−樹脂抱合体
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
AU2006292946B2 (en) * 2005-09-21 2009-12-10 Chong Kun Dang Pharmaceutical Corp. Novel resinate complex of s-clopidogrel and production method thereof
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
TW200812649A (en) 2006-03-16 2008-03-16 Tris Pharma Inc Modified release formulations containing drug-ion exchange resin complexes
US20080044462A1 (en) * 2006-04-06 2008-02-21 Collegium Pharmaceutical, Inc. Delaware Stabilized transdermal bupropion preparations
US20070286903A1 (en) * 2006-06-13 2007-12-13 Becicka Brian T Composition and method for taste masking
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
CN102164589A (zh) * 2008-09-24 2011-08-24 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
US20130177520A1 (en) * 2009-12-31 2013-07-11 Ranbaxy Laboratories Limited Taste masked dosage forms of bitter tasting anti-retroviral drugs
US8470375B1 (en) 2010-01-05 2013-06-25 Neos Therapeutics, Lp Method of formulating and designing liquid drug suspensions containing ion exchange resin particles
EP2621475A1 (de) 2010-10-02 2013-08-07 Link Research&Grants Corporation Behandlung von tinnitus und zugehörigen dysfunktionen des gehörs
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
EP2726066B1 (de) 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosisformen für amphetamin zur oralen verabreichung
US20130115253A1 (en) * 2011-11-07 2013-05-09 Mahendra R. Patel Sustained Release Suspension Preparation For Dextromethorphan
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
JP2013119550A (ja) 2011-12-08 2013-06-17 Medicinova Inc 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
US20150025103A1 (en) 2011-12-09 2015-01-22 Wochkardt Limited Oral liquid concentrate comprising brompheniramine, pseudoephedrine and dextromethorphan
EP2836201A1 (de) * 2011-12-14 2015-02-18 Wockhardt Limited Modifiziert freigesetzte pharmazeutische flüssigzusammensetzung mit brompheniramine, pseudoephedrin und dextromethorphan
EP2884961B1 (de) 2012-08-15 2019-03-06 Tris Pharma Inc. Methylphenidat-kautablette mit verlängerter freisetzung
MX2015009077A (es) * 2013-01-15 2015-09-10 Sun Pharmaceutical Ind Ltd Composicion estable que contiene fingolimod.
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
CN105407884B (zh) 2013-07-25 2019-04-30 美迪诺亚公司 降低甘油三酯、总胆固醇和低密度脂蛋白血液浓度的方法
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015076821A1 (en) * 2013-11-22 2015-05-28 Tris Pharma, Inc. Novel clonidine formulation
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
JP6469727B2 (ja) 2014-06-02 2019-02-13 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 線維症の抑制又は治療方法
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2967826C (en) 2014-11-26 2024-01-16 Medicinova, Inc. A combination of ibudilast and riluzole and methods of using same
MA41152A (fr) * 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
EP3503879A4 (de) 2016-08-26 2020-04-29 EXCIVA GmbH Zusammensetzung und verfahren dafür
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
CA3086153A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
US12514818B2 (en) 2017-12-18 2026-01-06 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CN111989091A (zh) * 2017-12-22 2020-11-24 Ddp特种电子材料美国公司 含有树脂颗粒的药物组合物
CN111971029A (zh) * 2017-12-22 2020-11-20 Ddp特种电子材料美国公司 含有交联的离子交换树脂的药物组合物
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
US12239620B2 (en) 2021-05-28 2025-03-04 Medicinova, Inc. Methods to decrease triglyceride synthesis in the liver
EP4658242A1 (de) 2023-02-03 2025-12-10 Tris Pharma, Inc. Natriumarmes oxybat zur einmaligen nacht
WO2025165367A1 (en) 2024-02-02 2025-08-07 Tris Pharma, Inc. Liquid clonidine extended release composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3155590A (en) * 1962-08-02 1964-11-03 Ncr Co Encapsulation process and its product
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3594470A (en) * 1968-02-19 1971-07-20 Abbott Lab Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
DE2246037B2 (de) * 1972-09-20 1975-02-27 Taeschner & Co, 8831 Kipfenberg Peroral anwendbares Arzneimittel mit verzögerter Resorbierbarkeit in Suspensionsform
US4221728A (en) * 1977-12-28 1980-09-09 General Electric Company Stabilized polycarbonate compositions
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
JPS6045845B2 (ja) * 1979-10-31 1985-10-12 田辺製薬株式会社 医薬物質含有マイクロカプセルの製法
JPS57197214A (en) * 1981-05-29 1982-12-03 Tanabe Seiyaku Co Ltd Rapid-releasing microcapsule and its preparation
US4847077A (en) * 1984-07-18 1989-07-11 Pennwalt Corporation Controlled release pharmaceutical preparations
CA1236023A (en) * 1984-07-18 1988-05-03 Yegnaswami Raghunathan Controlled release pharmaceutical preparations
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles
IE62100B1 (en) * 1986-07-30 1994-12-14 Fisons Corp Coated ion exchange resins
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof

Also Published As

Publication number Publication date
CA2001859C (en) 1995-10-31
JPH02172912A (ja) 1990-07-04
DK546389D0 (da) 1989-11-02
US4996047A (en) 1991-02-26
DE68912882D1 (de) 1994-03-17
AU4430689A (en) 1990-05-10
PH26699A (en) 1992-09-14
NZ231229A (en) 1992-03-26
DK546389A (da) 1990-05-03
CA2001859A1 (en) 1990-04-02
EP0367746B1 (de) 1994-02-02
EP0367746A2 (de) 1990-05-09
IE893537L (en) 1990-05-02
IE62765B1 (en) 1995-02-22
AU638420B2 (en) 1993-07-01
EP0367746A3 (de) 1991-01-23
DE68912882T2 (de) 1994-06-01
JP2941314B2 (ja) 1999-08-25
DK175659B1 (da) 2005-01-10

Similar Documents

Publication Publication Date Title
ATE101033T1 (de) Wirkstoff-harzkomplexe mit verzoegerter freigabe.
ATE67408T1 (de) Arzneimittel mit verzoegerter freigabe in oraler dosisform.
AU6764390A (en) Pharmaceutical granules and drug dosage units made therefrom
ATE202473T1 (de) Rasch freisetzende tablettenkerne mit unlöslichen arzneistoffen und mit einem retardüberzug
DE69624047D1 (de) Im unteren Teil des Verdauungstrakts freisetzende pharmazeutische Zubereitung in Form einer beschichteten Kapsel
ATE17189T1 (de) 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe.
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
DK1135112T3 (da) Oral formulering til gastrointestinal lægemiddeladministration
ATE124255T1 (de) Im dickdarm zerfallende, polypeptide enthaltende orale formulierungen.
MY107811A (en) Polyamine drug-resin complexes
AU574220B2 (en) Sustained release drug in ter polymer coat (pvc and pvacand pvom)
NL175882C (nl) Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
HK126193A (en) Drug particles having constant release
SE8701077D0 (sv) Pharmaceutical composition
ATE59551T1 (de) Feste orale arzneiformen mit gestaffelter wirkung zur verabreichung von wirkstoffen mit geschwuere erzeugender nebenwirkung.
EP0345883A3 (de) Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin
RU93043627A (ru) Фармацевтическая композиция, содержащая комплекс из смолы и полиаминового лекарственного препарата
NO171295C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat i form av et biologisk aktivt konjugert protein
ATE88630T1 (de) Fester koerper mit ueberzogenem kern.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee